A detailed history of Grandfield & Dodd, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 34,053 shares of IONS stock, worth $1.29 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
34,053
Previous 33,774 0.83%
Holding current value
$1.29 Million
Previous $1.46 Million 10.79%
% of portfolio
0.11%
Previous 0.1%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$36.45 - $47.7 $10,169 - $13,308
279 Added 0.83%
34,053 $1.62 Million
Q1 2024

May 03, 2024

BUY
$42.03 - $53.55 $28,160 - $35,878
670 Added 2.02%
33,774 $1.46 Million
Q4 2023

Jan 31, 2024

BUY
$43.39 - $51.63 $10,500 - $12,494
242 Added 0.74%
33,104 $1.67 Million
Q3 2023

Oct 25, 2023

BUY
$38.5 - $47.13 $7,045 - $8,624
183 Added 0.56%
32,862 $1.49 Million
Q2 2023

Aug 07, 2023

BUY
$34.73 - $43.33 $13,718 - $17,115
395 Added 1.22%
32,679 $1.34 Million
Q1 2023

Apr 28, 2023

BUY
$33.58 - $41.2 $27,199 - $33,372
810 Added 2.57%
32,284 $1.15 Million
Q4 2022

Jan 20, 2023

BUY
$37.12 - $46.52 $89,199 - $111,787
2,403 Added 8.27%
31,474 $0
Q3 2022

Nov 03, 2022

BUY
$36.54 - $48.66 $29,049 - $38,684
795 Added 2.81%
29,071 $1.29 Million
Q2 2022

Aug 01, 2022

BUY
$31.71 - $43.0 $8,720 - $11,825
275 Added 0.98%
28,276 $1.05 Million
Q1 2022

Apr 19, 2022

BUY
$29.88 - $37.04 $36,752 - $45,559
1,230 Added 4.59%
28,001 $1.04 Million
Q4 2021

Feb 08, 2022

BUY
$25.61 - $35.1 $130,098 - $178,308
5,080 Added 23.42%
26,771 $810,000
Q3 2021

Oct 28, 2021

BUY
$33.54 - $40.55 $21,398 - $25,870
638 Added 3.03%
21,691 $730,000
Q2 2021

Jul 28, 2021

BUY
$34.54 - $47.25 $24,178 - $33,075
700 Added 3.44%
21,053 $840,000
Q1 2021

Apr 22, 2021

BUY
$42.51 - $63.78 $30,224 - $45,347
711 Added 3.62%
20,353 $920,000
Q4 2020

Jan 29, 2021

BUY
$45.3 - $60.27 $27,406 - $36,463
605 Added 3.18%
19,642 $1.11 Million
Q3 2020

Nov 03, 2020

BUY
$47.45 - $62.95 $15,943 - $21,151
336 Added 1.8%
19,037 $900,000
Q2 2020

Jul 24, 2020

BUY
$46.85 - $61.05 $63,950 - $83,333
1,365 Added 7.87%
18,701 $1.1 Million
Q1 2020

May 14, 2020

BUY
$41.6 - $63.4 $27,456 - $41,844
660 Added 3.96%
17,336 $820,000
Q4 2019

Feb 07, 2020

BUY
$53.85 - $65.27 $46,041 - $55,805
855 Added 5.4%
16,676 $1.01 Million
Q3 2019

Oct 30, 2019

BUY
$59.06 - $72.15 $69,100 - $84,415
1,170 Added 7.99%
15,821 $948,000
Q2 2019

Jul 29, 2019

BUY
$62.09 - $86.14 $50,168 - $69,601
808 Added 5.84%
14,651 $942,000
Q1 2019

Apr 26, 2019

BUY
$52.92 - $81.17 $5,239 - $8,035
99 Added 0.72%
13,843 $1.12 Million
Q4 2018

Feb 12, 2019

BUY
$43.37 - $59.54 $7,156 - $9,824
165 Added 1.22%
13,744 $743,000
Q3 2018

Nov 02, 2018

BUY
$42.88 - $53.7 $4,716 - $5,907
110 Added 0.82%
13,579 $700,000
Q2 2018

Jul 27, 2018

BUY
$40.53 - $50.7 $3,242 - $4,056
80 Added 0.6%
13,469 $561,000
Q1 2018

May 04, 2018

SELL
$44.08 - $55.05 $12,342 - $15,414
-280 Reduced 2.05%
13,389 $590,000
Q4 2017

Feb 06, 2018

BUY
$50.3 - $64.39 $14,587 - $18,673
290 Added 2.17%
13,669 $688,000
Q3 2017

Nov 03, 2017

BUY
$45.56 - $59.57 $609,547 - $796,987
13,379
13,379 $678,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.38B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Grandfield & Dodd, LLC Portfolio

Follow Grandfield & Dodd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.